Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

Authors
Colleoni, M Price, KN Castiglione-Gertsch, M Gelber, RD Coates, AS Goldhirsch, A
Citation
M. Colleoni et al., Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil, LANCET, 354(9173), 1999, pp. 130-131
Citations number
5
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
LANCET
ISSN journal
01406736 → ACNP
Volume
354
Issue
9173
Year of publication
1999
Pages
130 - 131
Database
ISI
SICI code
0140-6736(19990710)354:9173<130:MDATOE>2.0.ZU;2-P
Abstract
Combined chemotherapy for early breast cancer with cyclophosphamide, methot rexate, and fluorouracil has low associated mortality, but related deaths w ere seen among women aged 65 years or older in International Breast Cancer Study Group trials.